Effects of Linagliptin on Endothelial Function and Global Arginine Bioavailability Ratio in Coronary Artery Disease Patients With Early Diabetes
Phase of Trial: Phase IV
Latest Information Update: 13 Jun 2018
Price : $35 *
At a glance
- Drugs Linagliptin (Primary)
- Indications Coronary artery disease; Type 2 diabetes mellitus
- Focus Pharmacodynamics
- 31 Aug 2018 Biomarkers information updated
- 21 Mar 2017 Status changed from active, no longer recruiting to completed.
- 29 Nov 2016 Planned End Date changed from 1 Dec 2016 to 1 Jan 2017.